Longeveron Inc. (LGVN) vs Skye Bioscience, Inc. (SKYE)
A side-by-side comparison of Longeveron Inc. and Skye Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LGVN
Longeveron Inc.
$2.37HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT
SKYE
Skye Bioscience, Inc.
$1.66HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
Total return — LGVN vs SKYE
growth of $100 · dividends reinvested · last 6yLGVN -99.7% (-61.2%/yr)SKYE -99.3% (-56.0%/yr)SKYE compounded faster over this window
LGVN SKYE
LGVN vs SKYE: by the numbers
- •SKYE is the larger company ($7M vs $7M market cap).
- •Both run net losses; SKYE's is the smaller (0.00% vs -1977.59% net margin).
Metrics side by side
Valuation
| Metric | LGVN | SKYE |
|---|---|---|
| P/S ratio | 6.08 | N/A |
| P/B ratio | 0.69 | N/A |
Profitability
| Metric | LGVN | SKYE |
|---|---|---|
| Gross margin | 69.76% | 0.00% |
| Operating margin | -1942.20% | 0.00% |
| Net margin | -1977.59% | 0.00% |
| ROE | -225.67% | N/A |
| ROIC | -211.58% | N/A |
Growth (annualized)
| Metric | LGVN | SKYE |
|---|---|---|
| Revenue CAGR (5Y) | -21.21% | N/A |
| Total return CAGR (5Y) | -62.60% | -60.42% |
Frequently asked
- How have LGVN and SKYE total returns compared?
- Over the past 5 years, LGVN delivered -62.60% and SKYE delivered -60.42% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.